Game-changing treatments for strokes revealed.
Ahead of world stroke day on 29th October, independent analysis firm Datamonitor Healthcare has revealed a number of blockbuster drugs, which could transform the way we prevent strokes.
As the second most common cause of death and a major cause of disability worldwide, it is estimated that, globally 15 million people suffer a stroke each year, of which 5 million die and 5 million are left permanently disabled.
Pradaxa, Xarelto and Eliquis, which have all been approved for use in the last 3 years, are new oral anticoagulant drugs, which offer an alternative to the standard stroke prevention therapy, warfarin, and have been hailed as potential game-changing drugs.
Dr Colin White, lead analyst at Datamonitor Healthcare said: “We have forecast that there will be 1.9 million cases of ischemic stroke, which are caused by blood clots, and approximately 280,000 incident cases of strokes caused by hemorrhages in 2020 across the US, Japan and the *five major EU markets.
“As atrial fibrillation is one of the major risk factors associated with stroke, and the aging global population is estimated to correlate with an increase in stroke incidence, we are expecting these novel oral anticoagulants to make a significant impact on the prevention of strokes.”
Datamonitor Healthcare estimates that the anticoagulants market will have a compound annual growth rate (CAGR) of 9-12% between 2012 and 2021.
Although there are concerns over bleeding reversals and antidotes, the benefits of these novel drugs may overcome these issues, leading to greater uptake. Physicians who are reluctant to prescribe novel therapies to their patients may consider that the use of blood plasma factors or dialysis to reverse bleeding is possible.
Either way, Eliquis is expected to become the market leader for novel anticoagulants between 2014 and 2017, with peak sales estimated between $1.95bn and $2.79bn in 2021.
Additional forecasts, opinion and research from Datamonitor Healthcare is available at www.datamonitorhealthcare.com
*5 major EU markets = France, Germany, Italy, Spain, UK
Media Contact: Lucy Giles @ MC2 | 0161 236 1352 | LucyG@mcmc.co.uk
About Datamonitor Healthcare
Datamonitor Healthcare is a world-leading provider of premium business information, delivering research and analysis of all aspects of the healthcare sector.
Notes to editors
Whenever citing an analyst or quote, please remember to use ‘Datamonitor Healthcare’ rather than ‘Datamonitor’.
For descriptive purposes, Datamonitor Healthcare is a “leading research and consulting firm.”
Whenever possible, please hyperlink:
The Datamonitor Healthcare name to www.datamonitorhealthcare.com
Any reports used to the correct URL for that listing on our Report Store.
Please note that all supplied to the media, is owned exclusively by Datamonitor Healthcare, is governed by our terms and conditions, and therefore must be referenced.
Posted in Uncategorized.